BioVentrix secures NUB Reimbursement Status 1 for Revivent TC transCatheter ventricular enhancement system in Germany

This article was originally published here

“Achieving NUB Reimbursement Status 1 is an important step towards increasing product adoption in Germany, where there’s a growing need for effective, less invasive, and cost-effective HF treatment options such as Revivent TC,” stated Kenneth Miller, president and chief executive officer of BioVentrix, Inc. 

BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive therapies for treating HF. 

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply